Evidence map›Paper›PMID 32561656›Full record

ArticleMolecular cancer research : MCR2020

The Long Noncoding RNA

Jianguo Huang, Mohit Sachdeva, Eric Xu, Timothy J Robinson, Lixia Luo, Yan Ma, Nerissa T Williams, Omar Lopez, Lisa D Cervia, Fan Yuan and 15 more

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cancer research : MCR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 28 citations in OpenAlex.

  1. Gm26550 Modulates Learning and Memory by Increasing IGF1 mRNA Expression and Stability in Nrf2Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. RNA-Binding Proteins: Modulators of Canonical Wnt Signaling Pathway.International journal of molecular sciences · 2025
    Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 9 institutions in 2 countries.

Jianguo HuangDepartment of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.
Mohit SachdevaDepartment of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.
Eric XuDepartment of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.
Timothy J RobinsonDepartment of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0003-0021-0668
Lixia LuoDepartment of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.
Yan MaDepartment of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.
Nerissa T WilliamsDepartment of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.
Omar LopezDepartment of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina.
Lisa D CerviaDepartment of Biomedical Engineering, Duke University, Durham, North Carolina.ORCID 0000-0002-8385-4014
Fan YuanDepartment of Biomedical Engineering, Duke University, Durham, North Carolina.ORCID 0000-0002-0687-6607
Xiaodi QinDuke Cancer Institute, Duke University Medical Center, Durham, North Carolina.
Dadong ZhangDuke Cancer Institute, Duke University Medical Center, Durham, North Carolina.
Kouros OwzarDuke Cancer Institute, Duke University Medical Center, Durham, North Carolina.
Nalan GokgozLunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.
Andrew SetoLunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.
Tomoyo OkadaMemorial Sloan Kettering Cancer Center, New York, New York.
Samuel SingerMemorial Sloan Kettering Cancer Center, New York, New York.
Irene L AndrulisLunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.
Jay S WunderLunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.
Alexander J LazarDepartments of Pathology, Genomic Medicine, and Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-6395-4499
Brian P RubinRobert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio.
Krista PiphoUniversity of Rochester Medical Center, Rochester, New York.ORCID 0000-0002-3332-2618
Stephano S MelloUniversity of Rochester Medical Center, Rochester, New York.ORCID 0000-0002-2484-086X
Jimena GiudiceDepartment of Cell Biology and Physiology, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.ORCID 0000-0002-3330-7784
David G KirschDepartment of Radiation Oncology, Duke University Medical Center, Durham, North Carolina. david.kirsch@duke.edu.ORCID 0000-0002-2086-205X
Duke Medical Center · USDuke University · USLunenfeld-Tanenbaum Research Institute · CAMemorial Sloan Kettering Cancer Center · USUniversity of Rochester Medical Center · USCleveland Clinic · USThe University of Texas MD Anderson Cancer Center · USUniversity of North Carolina at Chapel Hill · USUniversity of Toronto · CA

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI JOHN N. NORTON · 1985 to 2026
$174.8M
Statistical Methods for Cancer Clinical TrialsP01CA142538 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KOSOROK, MICHAEL R · 2010 to 2019
$21.3M
Advancing Cancer Therapy through Ground Breaking Research in Radiation BiologyR35CA197616 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI David Guy Kirsch · 2016 to 2026
$10.7M
Equipment -NEON transfection equipmentR01GM130866 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI GIUDICE, JIMENA · 2019 to 2023
$1.6M
NCI NIH HHS P01 CA142538NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA014236NCI NIH HHS R35 CA197616NIGMS NIH HHS R01 GM130866
6 · The paper itself

Abstract

Soft-tissue sarcomas (STS) are rare malignancies showing lineage differentiation toward diverse mesenchymal tissues. Half of all high-grade STSs develop lung metastasis with a median survival of 15 months. Here, we used a genetically engineered mouse model that mimics undifferentiated pleomorphic sarcoma (UPS) to study the molecular mechanisms driving metastasis. High-grade sarcomas were generated with Cre recombinase technology using mice with conditional mutations in

Indexed as

HumansNeoplasm MetastasisPC-3 CellsRNA, Long NoncodingRNA SplicingSarcomaTransfectionNEAT1 long non-coding RNA, humanRNA, Long Noncoding

Identifiers

PMID32561656
PMCPMC7541426
OpenAlexW3036806878

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.